Glia LP-BM5 Murine acquired immunodeficiency syndrome (MAIDS) Retroviral infection Peripheral neuropathy C57BL/6 (B6) mice develop peripheral neuropathy post-LP-BM5 infection, a murine model of HIV-1 infection, along with the up-regulation of select spinal cord cytokines. We investigated if calcitonin gene-related peptide (CGRP) contributed to the development of peripheral neuropathy by stimulating glial responses. An increased expression of lumbar spinal cord CGRP was observed in vivo, post-LP-BM5 infection. Consequently, in vitro CGRP co-treatments led to a microglial content-dependent attenuation of viral loads in spinal cord mixed glia infected with selected doses of LP-BM5. This inhibition was neither caused by the loss of glia nor induced via the direct inhibition of LP-BM5 by CGRP.
Introduction
As more effective antiretroviral therapies become available, human immunodeficiency virus (HIV)-1 infection is no longer represent a symbol of imminent death, but rather a chronic disease associated with a wide range of complications, including painful, HIV-associated peripheral neuropathy (Cornblath and McArthur, 1988; Miller, 1994; Hewitt et al., 1997; Simpson et al., 2002; Ellis et al., 2010) . Difficult to diagnose, HIV-associated peripheral neuropathy is often undertreated, which can, partially, be attributed to a lack of understanding of its pathophysiology (Cherry et al., 2005; Cettomai et al., 2013) . Consequently, the FDA has not yet approved a treatment for HIV-associated peripheral neuropathy (Ellis et al., 2010) .
In line with other studies, we have employed a murine retroviral isolate (LP-BM5) infection model to study HIV-1, as LP-BM5 induces a similar immunodeficiency syndrome (termed MAIDS) in susceptible C57BL/6 (B6) mice (Jolicoeur, 1991) . Our current work has shown that B6 mice infected with LP-BM5 displayed behavioral and pathological signs of peripheral neuropathy, both of which were associated with tissue-specific cytokine expression, including the elevation of selected pro-inflammatory cytokines (such as IL-12) in the lumbar spinal cord, post-LP-BM5 infection (Cao et al., 2012) .
Glial activation is a well-known contributor to HIV-associated neurological disorders (Kraft-Terry et al., 2009) . Although few studies have explored the roles of glial cells in the development of HIVassociated peripheral neuropathy, animal studies have shown that spinal cord glial activation and the subsequent production of proinflammatory cytokines, can contribute to the development of HIV-1, gp120-induced sensory hypersensitivity (a behavioral sign of painful peripheral neuropathy) (Milligan et al., 2000; Herzberg and Sagen, 2001; Wallace et al., 2007; Zheng et al., 2011) . As with HIV-1 in humans, the LP-BM5 virus can gain access to the central nervous system (CNS), leading to the direct infection of microglia and astrocytes (Sei et al., 1992) . Upon viral stimulation, glia have been reported to produce proinflammatory cytokines and cytotoxic factors capable of contributing to LP-BM5-induced neuronal death and CNS symptoms (Kustova et al., 1996 (Kustova et al., , 1998 Suzumura et al., 1998) .
Comprised of 37 amino acids, calcitonin gene-related peptide (CGRP) is a member of the calcitonin family and is predominantly produced by primary afferent neurons of small and medium diameters (Arulmani et al., 2004) . Following peripheral nerve injury, these subsets of primary afferent neurons have been shown to increase both the release and expression of CGRP in the spinal cord (Gardell et al., 2003; Zheng et al., 2008) . The administration of a CGRP 8-37 , a CGRP antagonist, has been reported to reduce peripheral nerve injury-induced sensory hypersensitivity (Bennett et al., 2000; Lee and Kim, 2007) . Furthermore, Journal of Neuroimmunology 279 (2015) 64-70
